,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,19006,4,3,,103401549,3034034,Unspecified,,,,,Calculated membrane partition coefficient (Kmemb),Other,15027870.0,
1,29139,4,3,,103401549,3034034,Unspecified,,,,,"Calculated dissociation constant (pKa, calculated with ACD/pKa)",Other,12477351.0,
2,29140,4,3,,103401549,3034034,Unspecified,,,,,Apparent value (pKa) calculated with ACD/pKa (experimental pKa value),Other,12477351.0,
3,33558,3,7,,103401549,3034034,Unspecified,,,,,The ability binding to (HSA) human serum albumin (Binding classified based on injection of compound at 80 uM concn.),Other,10821711.0,
4,72013,7,2,,103401549,3034034,Unspecified,,,100.0,EC50,Cytotoxicity against mouse mammary tumor FM3A cells representing a model of host,Confirmatory,11855978.0,
5,72015,6,2,,103401549,3034034,Unspecified,,,100.0,EC50,In vitro cytotoxic activity against mouse mammary tumor FM3A cells,Confirmatory,10937718.0,
6,72157,6,2,,103401549,3034034,Unspecified,,,100.0,EC50,In vitro cytotoxic activity tested in mouse mammary tumor FM3A cells,Confirmatory,15026051.0,
7,91481,4,7,,103401549,3034034,Unspecified,,,,,Binding constant against human serum albumin (HSA),Other,11728183.0,
8,116230,7,1,,103401549,3034034,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 160 mg/kg subcutaneous dose,Other,7009867.0,
9,116238,7,1,,103401549,3034034,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after 20 mg/kg subcutaneous dose,Other,7009867.0,
10,116242,9,1,,103401549,3034034,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 320 mg/kg subcutaneous dose,Other,7009867.0,
11,116250,7,1,,103401549,3034034,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) after 40 mg/kg subcutaneous dose,Other,7009867.0,
12,116254,7,1,,103401549,3034034,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 640 mg/kg subcutaneous dose,Other,7009867.0,
13,116376,7,1,,103401549,3034034,Unspecified,,,,,Antimalarial effect against trophozoite-induced Plasmodium berghei in mice (Mus musculus) at 80 mg/kg subcutaneous dose,Other,7009867.0,
14,119229,4,3,,103401549,3034034,Unspecified,,,,,Antimalarial activity against trophozoite-induced Plasmodium berghei in mice (Mus musculus),Other,7009867.0,
15,150618,9,2,,103401549,3034034,Unspecified,,,430.0,IC50,Concentration required for 50% inhibition at binding site of human P-Glycoprotein (P-gp) in one-affinity model,Confirmatory,12477351.0,
16,150735,9,2,,103401549,3034034,Active,,,12.0,Ki,High affinity constant at binding site of human P-Glycoprotein (P-gp) in two-affinity model,Confirmatory,12477351.0,
17,150736,3,8,,103401549,3034034,Unspecified,,,,,Fraction of high affinity at binding site of human P-Glycoprotein (P-gp) in two-affinity model,Other,12477351.0,
18,151997,8,2,,103401549,3034034,Unspecified,,,,,In vitro antimalarial activity against Plasmodium falciparum W-2 Indochina,Other,2657065.0,
19,151998,8,2,,103401549,3034034,Unspecified,,,,,In vitro antimalarial activity against Plasmodium falciparum D6 (Sierra Leone),Other,2657065.0,
20,158035,4,3,,103401549,3034034,Active,,,0.048,IC50,Inhibitory concentration against Plasmodium falciparum D6 infected erythrocytes,Confirmatory,8182707.0,
21,158037,4,3,,103401549,3034034,Active,,,0.1,IC50,Inhibitory concentration against Plasmodium falciparum W2 infected erythrocytes,Confirmatory,8182707.0,
22,158038,4,3,,103401549,3034034,Active,,,0.38,IC50,Inhibitory concentration against multidrug-resistant Plasmodium falciparum Dd2.,Confirmatory,12217353.0,
23,158639,7,2,,103401549,3034034,Unspecified,,,,,Effective dose ED50 against Plasmodium berghei N in mice (Mus musculus) malaria model after peroral administration,Other,12213073.0,
24,158642,10,1,,103401549,3034034,Unspecified,,,,,Effective dose ED50 against Plasmodium berghei N in mice (Mus musculus) malaria model after subcutaneous administration,Other,12213073.0,
25,158671,4,3,,103401549,3034034,Unspecified,,,,,Effective dose ED90 against Plasmodium berghei N in mice (Mus musculus) malaria model after peroral administration,Other,12213073.0,
26,158674,4,3,,103401549,3034034,Unspecified,,,,,Effective dose ED90 against Plasmodium berghei N in mice (Mus musculus) malaria model after subcutaneous administration,Other,12213073.0,
27,158708,6,3,,103401549,3034034,Unspecified,,,250.0,IC50,In vitro inhibitory concentration against ferriprotoporphyrin in biomineralisation assay (FBIT),Confirmatory,12873511.0,
28,158715,4,4,,103401549,3034034,Active,,,0.38,IC50,Inhibition against Plasmodium falciparum Dd2 in erythrocytes in semiautomated micro dilution assay,Confirmatory,12798326.0,
29,158844,8,2,,103401549,3034034,Unspecified,,,,,Inhibitory activity against Plasmodium falciparum D6,Other,12213073.0,
30,158845,8,2,,103401549,3034034,Unspecified,,,,,Inhibitory activity against Plasmodium falciparum K1,Other,12213073.0,
31,158846,8,2,,103401549,3034034,Unspecified,,,,,Inhibitory activity against Plasmodium falciparum NF54,Other,12213073.0,
32,158848,8,2,,103401549,3034034,Unspecified,,,,,Inhibitory activity against Plasmodium falciparum W2,Other,12213073.0,
33,158849,8,1,,103401549,3034034,Active,,,0.38,IC50,Inhibitory activity against Plasmodium falciparum Dd2 in erythrocytes,Confirmatory,11212126.0,
34,158858,6,3,,103401549,3034034,Unspecified,,,,,Inhibitory concentration against ferriprotoporphyrin in biomineralisation (FBIT),Other,12873511.0,
35,158864,4,3,,103401549,3034034,Active,,,0.096,IC50,Antimalarial activity against Plasmodium falciparum 3D7 in erythrocytes,Confirmatory,11844668.0,
36,158865,4,3,,103401549,3034034,Active,,,0.38,IC50,Antimalarial activity against Plasmodium falciparum Dd2 in erythrocytes,Confirmatory,11844668.0,
37,159014,3,3,,103401549,3034034,Active,,,,,Minimum inhibitory concentration (IC99) against Plasmodium falciparum K1 infected erythrocytes,Other,8182707.0,
38,159026,3,4,,103401549,3034034,Unspecified,,,,,Inhibitory ratio on proliferation of Plasmodium falciparum at 0.1 uM,Other,11549443.0,
39,159840,6,2,,103401549,3034034,Unspecified,,,,,Compound was evaluated for its antimalarial activity in vitro on Plasmodium falciparum,Other,12127529.0,
40,159892,6,2,,103401549,3034034,Unspecified,,,,,Effective oral dose ED50 against Plasmodium yoelii sspNS,Other,12213073.0,
41,159899,9,1,,103401549,3034034,Unspecified,,,,,Effective subcutaneous dose ED50 against Plasmodium yoelii sspNS,Other,12213073.0,
42,159900,3,3,,103401549,3034034,Unspecified,,,,,Effective oral dose ED90 against Plasmodium yoelii sspNS,Other,12213073.0,
43,159907,5,1,,103401549,3034034,Unspecified,,,,,Effective subcutaneous dose ED90 against Plasmodium yoelii sspNS,Other,12213073.0,
44,160053,6,2,,103401549,3034034,Active,,,0.11,EC50,In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCR3,Confirmatory,10937718.0,
45,160054,6,2,,103401549,3034034,Active,,,0.11,EC50,In vitro antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCR3,Confirmatory,11855978.0,
46,160056,6,2,,103401549,3034034,Active,,,0.11,EC50,In vitro antimalarial activity against Plasmodium falciparum FCR3,Confirmatory,15026051.0,
47,205267,9,2,,103401549,3034034,Active,,,4.4,IC50,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex,Confirmatory,2579237.0,
48,205268,4,7,,103401549,3034034,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
49,211647,5,2,,103401549,3034034,Unspecified,,,,,Compound was evaluated for toxicity on Human kidney epithelial (Graham cells) at a dose of 100 ug/mL; Not toxic,Other,12127529.0,
50,227386,3,4,,103401549,3034034,Unspecified,,,,,Antiplasmodial potency relative to chloroquine in ferriprotoporphyrin biomineralisation assay,Other,12873511.0,
51,227925,6,2,,103401549,3034034,Unspecified,,,556.0,Kd,The compound was estimated for biosensor analysis,Confirmatory,10821711.0,
52,232807,3,4,,103401549,3034034,Unspecified,,,,,Selective toxicity- EC50 value of FM3A / EC50 value of Plasmodium falciparum,Other,11855978.0,
53,233027,3,4,,103401549,3034034,Unspecified,,,,,Relative activity against FM3A cells and Plasmodium falciparum FCR3,Other,15026051.0,
54,233780,3,5,,103401549,3034034,Unspecified,,,,,"The ratio of SD90 of the quinine hydrochloride, to the SD90 of the test substance for the Dose of 74.5 mg/kg",Other,7009867.0,
55,234946,4,4,,103401549,3034034,Unspecified,,,,,Selectivity is the ratio of mean EC50 value against FA3A cells to that of EC50 value against Plasmodium falciparum,Other,10937718.0,
56,237685,4,3,,103401549,3034034,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
57,243422,3,10,,103401549,3034034,Unspecified,116241312.0,1576.0,,,log (1/Km) value for human liver microsome cytochrome P450 3A4,Other,15990295.0,
58,262947,6,7,,103401549,3034034,Active,84028191.0,1565.0,1.8,IC50,Inhibition of human CYP2D6 expressed in Escherichia coli JM109,Confirmatory,16610785.0,
59,264018,4,3,,103401549,3034034,Active,,,0.11,EC50,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum FCR3,Confirmatory,16524728.0,
60,264019,4,4,,103401549,3034034,Unspecified,,,100.0,EC50,Cytotoxicity against mouse FM3A cell line,Confirmatory,16524728.0,
61,264020,3,5,,103401549,3034034,Unspecified,,,,,Selectivity ratio of EC50s against Plasmodium falciparum FCR3 to mice (Mus musculus) FM3A cells,Other,16524728.0,
62,279383,4,3,,103401549,3034034,Active,,,0.06652000000000001,IC50,Growth inhibition of Plasmodium falciparum ring stage in infected erythrocytes by DAPI growth assay,Confirmatory,17116676.0,
63,279384,4,3,,103401549,3034034,Active,,,0.06919,IC50,Growth inhibition of Plasmodium falciparum ring stage in infected erythrocytes by DAPI growth assay,Confirmatory,17116676.0,
64,279385,4,3,,103401549,3034034,Active,,,0.06277,IC50,Growth inhibition of Plasmodium falciparum as reduced [3H]hypoxanthine incorporation,Confirmatory,17116676.0,
65,298287,8,1,,103401549,3034034,Active,,,10.0,IC50,Antiprion activity in ScN2a cells assessed as inhibition of protease-resistant prion protein accumulation,Confirmatory,17850126.0,
66,299661,8,1,,103401549,3034034,Inactive,,,,,Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 25923 by broth microdilution method,Other,17570664.0,
67,299662,8,1,,103401549,3034034,Inactive,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus CMAH 0430 by broth microdilution method,Other,17570664.0,
68,299663,8,1,,103401549,3034034,Inactive,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus CMAH 0504 by broth microdilution method,Other,17570664.0,
69,299664,8,1,,103401549,3034034,Inactive,,,,,Antibacterial activity against methicillin-resistant Staphylococcus aureus CMAH 0515 by broth microdilution method,Other,17570664.0,
70,299675,3,4,,103401549,3034034,Unspecified,,,,,Toxicity in human erythrocytes assessed as hemolytic activity at 2000 ug/ml after 1 hr,Other,17570664.0,
71,299676,3,4,,103401549,3034034,Unspecified,,,,,Toxicity in human erythrocytes assessed as hemolytic activity at 1000 ug/ml after 1 hr,Other,17570664.0,
72,299677,3,4,,103401549,3034034,Unspecified,,,,,Toxicity in human erythrocytes assessed as hemolytic activity at 500 ug/ml after 1 hr,Other,17570664.0,
73,299678,3,4,,103401549,3034034,Unspecified,,,,,Toxicity in human erythrocytes assessed as hemolytic activity at 250 ug/ml after 1 hr,Other,17570664.0,
74,316375,7,1,,103401549,3034034,Unspecified,,,,,Binding affinity to heme in aqueous solution,Other,18023189.0,
75,316376,4,3,,103401549,3034034,Active,,,0.011000000000000001,IC50,Antimalarial activity against Plasmodium falciparum D6 in MSF assay,Confirmatory,18023189.0,
76,316377,4,3,,103401549,3034034,Active,,,0.06,IC50,Antimalarial activity against Plasmodium falciparum W2 in MSF assay,Confirmatory,18023189.0,
77,322126,8,2,,103401549,3034034,Unspecified,,,,,In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay,Other,17371812.0,
78,322127,8,2,,103401549,3034034,Unspecified,,,,,In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay,Other,17371812.0,
79,322128,8,2,,103401549,3034034,Unspecified,,,,,In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs by SYBR green fluorescence assay,Other,17371812.0,
80,322129,8,2,,103401549,3034034,Unspecified,,,,,In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green fluorescence assay,Other,17371812.0,
81,322130,8,2,,103401549,3034034,Unspecified,,,,,In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay,Other,17371812.0,
82,322131,8,2,,103401549,3034034,Unspecified,,,,,In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay,Other,17371812.0,
83,322132,8,2,,103401549,3034034,Unspecified,,,,,In vitro antimalarial activity against Plasmodium falciparum D6 after 72 hrs in SYBR green fluorescence assay,Other,17371812.0,
84,322133,8,2,,103401549,3034034,Unspecified,,,,,In vitro antimalarial activity against Plasmodium falciparum W2 after 72 hrs in SYBR green fluorescence assay,Other,17371812.0,
85,322134,8,2,,103401549,3034034,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum D6 as reduced [3H]hypoxanthine uptake after 72 hrs,Other,17371812.0,
86,322135,8,2,,103401549,3034034,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum W2 as reduced [3H]hypoxanthine uptake after 72 hrs,Other,17371812.0,
87,324385,3,4,,103401549,3034034,Unspecified,,,,,Induction of light chain 3-GFP level in human H4 cells at 6.9 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
88,324437,3,4,,103401549,3034034,Unspecified,,,,,Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 6.9 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
89,324489,3,4,,103401549,3034034,Unspecified,,,,,Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 6.9 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
90,324541,3,4,,103401549,3034034,Unspecified,,,,,Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 6.9 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
91,324576,3,4,,103401549,3034034,Unspecified,,,,,Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 2 hrs relative to control,Other,18024584.0,
92,324577,3,4,,103401549,3034034,Unspecified,,,,,Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 4 hrs relative to control,Other,18024584.0,
93,324578,3,4,,103401549,3034034,Unspecified,,,,,Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 8 hrs relative to control,Other,18024584.0,
94,324582,3,4,,103401549,3034034,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 1 hr relative to control,Other,18024584.0,
95,324583,3,4,,103401549,3034034,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 2 hrs relative to control,Other,18024584.0,
96,324584,3,4,,103401549,3034034,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 4 hrs relative to control,Other,18024584.0,
97,324585,3,4,,103401549,3034034,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 24 hrs relative to control,Other,18024584.0,
98,327169,3,3,,103401549,3034034,Unspecified,,,,,Apparent permeability across parallel artificial membrane,Other,18348514.0,
99,327170,4,6,,103401549,3034034,Unspecified,113576.0,213.0,309.03,Kd,Binding affinity to human serum albumin by PAMPA method,Confirmatory,18348514.0,
100,333755,5,1,,103401549,3034034,Unspecified,,,,,Antimalarial activity as reduced heme degradation in Plasmodium falciparum infected human erythrocytes,Other,15620250.0,
101,334842,5,1,,103401549,3034034,Unspecified,,,,,Antimalarial activity after 24 hrs against Plasmodium falciparum D6 infected type A+ human erythrocytes by [3H]hypoxanthine uptake,Other,8229016.0,
102,334843,5,1,,103401549,3034034,Unspecified,,,,,Antimalarial activity after 24 hrs against Plasmodium falciparum W2 infected in type A+ human erythrocytes by [3H]hypoxanthine uptake,Other,8229016.0,
103,334844,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human KB cells to ED50 for Plasmodium falciparum D6",Other,8229016.0,
104,334845,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human KB cells to ED50 for Plasmodium falciparum W2",Other,8229016.0,
105,335151,7,1,,103401549,3034034,Unspecified,,,,,Antimalarial activity after 24 hrs against chloroquine-sensitive Plasmodium falciparum D6 infected type A+ human erythrocytes by [3H]hypoxanthine uptake,Other,8254346.0,
106,335152,7,1,,103401549,3034034,Unspecified,,,,,Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum W2 infected type A+ human erythrocytes by [3H]hypoxanthine uptake,Other,8254346.0,
107,335153,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ED50 for human KB cells to ED50 for chloroquine-sensitive Plasmodium falciparum D6",Other,8254346.0,
108,335154,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ED50 for human KB cells to ED50 for chloroquine-resistant Plasmodium falciparum W2",Other,8254346.0,
109,336324,8,3,,103401549,3034034,Unspecified,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum Indochina W2 after 24 to 60 hrs by [G-H3]hypoxanthine uptake,Other,8289064.0,
110,336325,8,3,,103401549,3034034,Unspecified,,,,,Antimalarial activity against mefloquine-resistant Plasmodium falciparum D6 (Sierra Leone) after 24 to 60 hrs by [G-H3]hypoxanthine uptake,Other,8289064.0,
111,337512,7,1,,103401549,3034034,Unspecified,,,,,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected type A+ human erythrocytes by [3H]hypoxanthine uptake,Other,8450318.0,
112,337513,7,1,,103401549,3034034,Unspecified,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected type A+ human erythrocytes by [3H]hypoxanthine uptake,Other,8450318.0,
113,337514,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human multidrug-sensitive KB3 cells,Other,8450318.0,
114,337515,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human multidrug-resistant KBV1 cells,Other,8450318.0,
115,337516,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against mouse P388 cells,Other,8450318.0,
116,337517,7,1,,103401549,3034034,Unspecified,,,,,Antimalarial activity after 24 hrs against chloroquine-sensitive Plasmodium falciparum D6 infected type A+ human erythrocytes by [3H]hypoxanthine uptake,Other,8450319.0,
117,337518,7,1,,103401549,3034034,Unspecified,,,,,Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum W2 infected type A+ human erythrocytes by [3H]hypoxanthine uptake,Other,8450319.0,
118,337519,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human BCA1 cells after 3 days by sulforhodamine B assay,Other,8450319.0,
119,337520,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human HT1080 cells after 3 days by sulforhodamine B assay,Other,8450319.0,
120,337521,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human LUC1 cells after 3 days by sulforhodamine B assay,Other,8450319.0,
121,337522,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells after 3 days by sulforhodamine B assay,Other,8450319.0,
122,337523,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human Col1 cells after 3 days by sulforhodamine B assay,Other,8450319.0,
123,337524,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay,Other,8450319.0,
124,337525,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human KBV1 cells after 3 days by sulforhodamine B assay,Other,8450319.0,
125,337526,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against mouse P388 cells after 2 days by sulforhodamine B assay,Other,8450319.0,
126,337527,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human A431 cells after 3 days by sulforhodamine B assay,Other,8450319.0,
127,337528,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human LNCAP cells after 3 days by sulforhodamine B assay,Other,8450319.0,
128,337529,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human ZR-75-1 cells after 3 days by sulforhodamine B assay,Other,8450319.0,
129,337530,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human BCA1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D6",Other,8450319.0,
130,337531,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human BCA1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W2",Other,8450319.0,
131,337532,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human HT1080 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D6",Other,8450319.0,
132,337533,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human HT1080 cells to ED50 for chloroquine-resistant Plasmodium falciparum W2",Other,8450319.0,
133,337534,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human LUC1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D6",Other,8450319.0,
134,337535,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human LUC1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W2",Other,8450319.0,
135,337536,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human MEL2 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D6",Other,8450319.0,
136,337537,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human MEL2 cells to ED50 for chloroquine-resistant Plasmodium falciparum W2",Other,8450319.0,
137,337538,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human COL1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D6",Other,8450319.0,
138,337539,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human COL1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W2",Other,8450319.0,
139,337540,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-sensitive Plasmodium falciparum D6",Other,8450319.0,
140,337541,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-resistant Plasmodium falciparum W2",Other,8450319.0,
141,337542,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human KB-V1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D6",Other,8450319.0,
142,337543,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human KB-V1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W2",Other,8450319.0,
143,337544,3,6,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for mice (Mus musculus) P388 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D6",Other,8450319.0,
144,337545,3,6,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for mice (Mus musculus) P388 cells to ED50 for chloroquine-resistant Plasmodium falciparum W2",Other,8450319.0,
145,337546,3,5,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human A431 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D6",Other,8450319.0,
146,337547,3,5,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human A431 cells to ED50 for chloroquine-resistant Plasmodium falciparum W2",Other,8450319.0,
147,337548,3,5,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human LNCaP cells to ED50 for chloroquine-sensitive Plasmodium falciparum D6",Other,8450319.0,
148,337549,3,5,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human LNCaP cells to ED50 for chloroquine-resistant Plasmodium falciparum W2",Other,8450319.0,
149,337550,3,5,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human ZR-75-1 cells to ED50 for chloroquine-sensitive Plasmodium falciparum D6",Other,8450319.0,
150,337551,3,5,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human ZR-75-1 cells to ED50 for chloroquine-resistant Plasmodium falciparum W2",Other,8450319.0,
151,337669,7,1,,103401549,3034034,Unspecified,,,,,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes after 24 hrs by [3H]hypoxanthine uptake,Other,7528786.0,
152,337670,7,1,,103401549,3034034,Unspecified,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected human erythrocytes after 24 hrs by [3H]hypoxanthine uptake,Other,7528786.0,
153,337671,3,5,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-sensitive Plasmodium falciparum D6",Other,7528786.0,
154,337672,3,5,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human KB cells to ED50 for chloroquine-resistant Plasmodium falciparum W2",Other,7528786.0,
155,338767,8,3,,103401549,3034034,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum D6 in human erythrocytes after 24 hrs by [3H]hypoxanthine uptake,Other,1800638.0,
156,338768,8,3,,103401549,3034034,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum W2 in human erythrocytes after 24 hrs by [3H]hypoxanthine uptake,Other,1800638.0,
157,354687,8,2,,103401549,3034034,Unspecified,,,,,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 as [3H]hypoxanthine uptake,Other,8786363.0,
158,354688,8,2,,103401549,3034034,Unspecified,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 as [3H]hypoxanthine uptake,Other,8786363.0,
159,354806,8,2,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human KB cells,Other,8759172.0,
160,354807,8,2,,103401549,3034034,Unspecified,,,,,Antiplasmodial activity against Plasmodium falciparum D6,Other,8759172.0,
161,354808,3,3,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of IC50 for human KB cells to IC50 for Plasmodium falciparum D6",Other,8759172.0,
162,354809,8,2,,103401549,3034034,Unspecified,,,,,Antiplasmodial activity against Plasmodium falciparum W2,Other,8759172.0,
163,354810,3,3,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of IC50 for human KB cells to IC50 for Plasmodium falciparum W2",Other,8759172.0,
164,357906,8,2,,103401549,3034034,Unspecified,,,,,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6,Other,11575956.0,
165,357907,8,2,,103401549,3034034,Unspecified,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2,Other,11575956.0,
166,358504,6,2,,103401549,3034034,Active,,,,IC50,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum FCA 20 Ghana by [3H]hypoxanthine uptake,Confirmatory,11170658.0,
167,358505,6,2,,103401549,3034034,Active,,,,IC50,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 Indochina by [3H]hypoxanthine uptake,Confirmatory,11170658.0,
168,359665,8,3,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human KB cells,Other,1294700.0,
169,359666,8,3,,103401549,3034034,Unspecified,,,,,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6,Other,1294700.0,
170,359667,8,3,,103401549,3034034,Unspecified,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2,Other,1294700.0,
171,360935,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human KB cells after 72 hrs,Other,11421741.0,
172,360936,10,1,,103401549,3034034,Unspecified,,,,,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 by [3H]hypoxanthine uptake,Other,11421741.0,
173,361168,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum D6",Other,11421741.0,
174,361169,8,2,,103401549,3034034,Unspecified,,,,,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 by [3H]hypoxanthine uptake,Other,11421741.0,
175,361170,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-resistant Plasmodium falciparum W2",Other,11421741.0,
176,377944,5,1,,103401549,3034034,Unspecified,,,55.4,ED50,Cytotoxicity against human KB cells after 72 hrs by SRB assay,Confirmatory,9917283.0,
177,377945,4,3,,103401549,3034034,Active,,,0.02338,IC50,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes as [3H]hypoxanthine uptake after 24 hrs,Confirmatory,9917283.0,
178,377946,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum D6",Other,9917283.0,
179,377947,4,3,,103401549,3034034,Active,,,0.25,IC50,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected human erythrocytes as [3H]hypoxanthine uptake after 24 hrs,Confirmatory,9917283.0,
180,377948,3,4,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of ED50 for human KB cells to IC50 for chloroquine-sensitive Plasmodium falciparum W2",Other,9917283.0,
181,378082,5,1,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human KB cells,Other,16933872.0,
182,378393,6,2,,103401549,3034034,Unspecified,,,,,Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6,Other,16933872.0,
183,378395,6,2,,103401549,3034034,Unspecified,,,,,Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2,Other,16933872.0,
184,378397,3,3,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of IC50 for human KB cells to IC50 for Plasmodium falciparum D6",Other,16933872.0,
185,378398,3,3,,103401549,3034034,Unspecified,,,,,"Selectivity index, ratio of IC50 for human KB cells to IC50 for Plasmodium falciparum W2",Other,16933872.0,
186,378977,8,2,,103401549,3034034,Unspecified,,,,,Antimalarial activity after 48 hrs against Plasmodium falciparum W2 by [3H]hypoxanthine uptake,Other,16441070.0,
187,378979,8,2,,103401549,3034034,Unspecified,,,,,Antimalarial activity after 48 hrs against Plasmodium falciparum D6 by [3H]hypoxanthine uptake,Other,16441070.0,
188,386623,4,8,,103401549,3034034,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
189,386625,9,5,,103401549,3034034,Unspecified,313104181.0,6580.0,51.6,IC50,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy,Confirmatory,18788725.0,
190,388306,6,2,,103401549,3034034,Inactive,,,,Ki,Inhibition of Plasmodium falciparum recombinant carbonic anhydrase,Confirmatory,18805693.0,
191,393144,6,2,,103401549,3034034,Unspecified,,,,,Antitubercular activity against Mycobacterium tuberculosis H37Rv after 5 days by microplate alamar blue assay,Other,19188070.0,
192,401645,6,4,,103401549,3034034,Unspecified,,,7400000.0,IC50,Inhibition of beta-hematin formation by BHIA assay,Confirmatory,15921407.0,
193,401646,6,2,,103401549,3034034,Unspecified,,,360000000.0,IC50,Displacement of methyl green dye from DNA,Confirmatory,15921407.0,
194,402124,8,2,,103401549,3034034,Unspecified,,,,,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 infected human erythrocytes by [3H]hypoxanthine uptake,Other,9249972.0,
195,402125,8,2,,103401549,3034034,Unspecified,,,,,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected human erythrocytes by [3H]hypoxanthine uptake,Other,9249972.0,
196,402126,8,2,,103401549,3034034,Unspecified,,,,,Antiplasmodial activity against Plasmodium falciparum K1 infected human erythrocytes by [3H]hypoxanthine uptake,Other,9249972.0,
197,402140,8,2,,103401549,3034034,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum D6 by [3H]hypoxanthine uptake,Other,9134742.0,
198,402141,8,2,,103401549,3034034,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum W2 by [3H]hypoxanthine uptake,Other,9134742.0,
199,402142,3,3,,103401549,3034034,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum D6 by [3H]hypoxanthine uptake relative to gedunin,Other,9134742.0,
200,402143,3,3,,103401549,3034034,Unspecified,,,,,Antimalarial activity against Plasmodium falciparum W2 by [3H]hypoxanthine uptake relative to gedunin,Other,9134742.0,
201,402145,8,2,,103401549,3034034,Unspecified,,,,,Cytotoxicity against human KB cells,Other,9134742.0,
202,404304,3,10,,103401549,3034034,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
203,417167,6,2,,103401549,3034034,Inconclusive,,,,IC50,Cytotoxicity against human A2780 cells,Confirmatory,19282186.0,
204,417168,6,2,,103401549,3034034,Inconclusive,,,,IC50,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 by SYBR green assay,Confirmatory,19282186.0,
205,417170,6,2,,103401549,3034034,Active,,,0.22,IC50,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FCM29 by SYBR green assay,Confirmatory,19282186.0,
206,419115,3,4,,103401549,3034034,Unspecified,,,,,Binding affinity to heme assessed as binding constant for stepwise binding of 2 equivalent of drug to 1 molecule of heme in presence of 40% DMSO by UV-visible spectroscopy,Other,19284751.0,
207,419116,3,4,,103401549,3034034,Unspecified,,,,,Binding affinity to heme assessed as binding constant for stepwise binding of 2 molecules of heme to 1 equivalent of drug in presence of 40% DMSO by UV-visible spectroscopy,Other,19284751.0,
208,420491,6,2,,103401549,3034034,Active,,,0.012,IC50,Antimalarial activity against Plasmodium falciparum K1,Confirmatory,19084293.0,
209,444050,7,1,,103401549,3034034,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
210,444051,6,2,,103401549,3034034,Unspecified,,,,,Total clearance in human,Other,20070106.0,
211,444052,6,2,,103401549,3034034,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
212,444053,6,2,,103401549,3034034,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
213,444054,6,1,,103401549,3034034,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
214,444055,3,3,,103401549,3034034,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
215,444056,3,3,,103401549,3034034,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
216,444057,3,3,,103401549,3034034,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
217,444058,6,2,,103401549,3034034,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
218,461596,3,3,,103401549,3034034,Unspecified,,,,,"Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as inhibition of parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 5 days post infection",Other,20017491.0,
219,461599,3,3,,103401549,3034034,Unspecified,,,,,"Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 5 days post infection",Other,20017491.0,
220,461602,3,3,,103401549,3034034,Unspecified,,,,,"Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 7 days post infection",Other,20017491.0,
221,461605,3,3,,103401549,3034034,Unspecified,,,,,"Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 10 days post infection",Other,20017491.0,
222,461608,3,3,,103401549,3034034,Unspecified,,,,,"Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 14 days post infection",Other,20017491.0,
223,461611,3,3,,103401549,3034034,Unspecified,,,,,"Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as average parasitaemia at 200 mg/kg, perorally administered 1 day after infection measured after 21 days post infection",Other,20017491.0,
224,461617,3,3,,103401549,3034034,Unspecified,,,,,"Antiplasmodial activity against Plasmodium berghei NK65 infected in Swiss Webster mice (Mus musculus) assessed as parasitaemia cure at 200 mg/kg, perorally administered 1 day after infection measured after 28 days post infection",Other,20017491.0,
225,466460,7,1,,103401549,3034034,Unspecified,,,,IC50,Antimalarial activity against cycloguanil-resistant Plasmodium falciparum CDC1 assessed as inhibition of ring stage parasitaemia after 48 hrs by Giemsa staining,Confirmatory,20149652.0,
226,467611,3,6,,103401549,3034034,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
227,467612,3,6,,103401549,3034034,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
228,467613,5,3,,103401549,3034034,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
229,472367,3,3,,103401549,3034034,Active,,,0.18,IC50,Antimalarial activity against Plasmodium falciparum Nigerian assessed as [3H]hypoxanthine uptake after 48 hrs by liquid scintillation counting,Confirmatory,19747753.0,
230,481439,3,4,,103401549,3034034,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
231,481442,3,6,,103401549,3034034,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
232,496819,4,2,,103401549,3034034,Unspecified,,,54.0,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
233,513158,5,2,,103401549,3034034,Inactive,,,,IC50,Inhibition of heme crystallization after 16 hrs,Confirmatory,16816845.0,
234,513176,1,3,,103401549,3034034,Inactive,,,,,Displacement of [3H]astemizole from free heme crystal at 15 uM after 16 hrs by scintillation counting,Other,16816845.0,
235,540209,4,3,,103401549,3034034,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
236,540210,4,3,,103401549,3034034,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
237,540211,2,5,,103401549,3034034,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
238,540212,4,3,,103401549,3034034,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
239,540213,4,3,,103401549,3034034,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
240,558053,2,3,,103401549,3034034,Active,,,0.066,IC50,Antimicrobial activity against Plasmodium falciparum harboring CVMNT genotype after 72 hrs by SYBR green I assay,Confirmatory,19258269.0,
241,558054,2,3,,103401549,3034034,Active,,,0.07,IC50,Antimicrobial activity against Plasmodium falciparum harboring SVMNT genotype after 72 hrs by SYBR green I assay,Confirmatory,19258269.0,
242,581962,6,1,,103401549,3034034,Active,,,0.07396,IC50,Antimicrobial activity against leupeptin resistant-Plasmodium falciparum HB3-leuR1 mutant infected in erythrocytes assessed as growth inhibition after 72 hrs by SYBR Green I-based fluorescence assay,Confirmatory,18443109.0,
243,581964,6,1,,103401549,3034034,Active,,,0.07712999999999999,IC50,Antimicrobial activity against wild type Plasmodium falciparum HB3 infected in erythrocytes assessed as growth inhibition after 72 hrs by SYBR Green I-based fluorescence assay,Confirmatory,18443109.0,
244,586923,1,3,,103401549,3034034,Unspecified,,,,,"Resistant index, ratio of EC50 for tafenoquine-resistant promastigotes of Leishmania major R4 to EC50 for promastigotes of Leishmania major MHOM/JL/80/Friedlin",Other,21199921.0,
245,586924,4,2,,103401549,3034034,Active,,,9.53,EC50,Antileishmanial activity against tafenoquine-resistant promastigotes of Leishmania major R4 assessed as inhibition of parasite growth after 72 hrs by MTT assay,Confirmatory,21199921.0,
246,586925,4,2,,103401549,3034034,Active,,,9.41,EC50,Antileishmanial activity against wild type promastigotes of Leishmania major MHOM/JL/80/Friedlin assessed as inhibition of parasite growth after 72 hrs by MTT assay,Confirmatory,21199921.0,
247,588209,2,3,,103401549,3034034,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
248,588210,2,4,,103401549,3034034,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
249,588988,1,9,,103401549,3034034,Unspecified,313104181.0,6580.0,,,"Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OCT1",Other,20190787.0,
250,589039,1,10,,103401549,3034034,Unspecified,116241312.0,1576.0,,,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP3A4",Other,,
251,600551,3,3,,103401549,3034034,Active,,,0.14,IC50,Antimicrobial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of [3H] hypoxanthine incorporation after 24 hrs by scintillation counting,Confirmatory,21377771.0,
252,600553,1,4,,103401549,3034034,Unspecified,,,,,Toxicity in human RBC assessed as hemolysis at 100 uM after 48 hrs,Other,21377771.0,
253,600554,3,2,,103401549,3034034,Unspecified,,,65.8,IC50,Inhibition of beta-haematin formation after 24 hrs by microtiter plate assay,Confirmatory,21377771.0,
254,600556,1,5,,103401549,3034034,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging activity at 80 uM after 30 mins,Other,21377771.0,
255,624349,1,2,,92308761,3034034,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
256,625294,1,3,,103401549,3034034,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data,Other,22194678.0,
257,651828,1,2,,92308761,3034034,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
258,666967,2,3,,103401549,3034034,Unspecified,,,,,Antimalarial activity against trophozoite stage of chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocytes after 48 hrs,Other,22652224.0,
259,678785,3,6,,103401549,3034034,Unspecified,81882176.0,20518.0,2.8,IC50,TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 1 uM) in Xenopus laevis oocytes,Confirmatory,12176030.0,
260,678794,3,6,,103401549,3034034,Unspecified,189046191.0,20517.0,0.28,IC50,TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 1 uM) in Xenopus laevis oocytes,Confirmatory,12176030.0,
261,678968,3,6,,103401549,3034034,Unspecified,81872789.0,29503.0,13.0,IC50,TP_TRANSPORTER: inhibition of TEA uptake (in the presence of bicarbonate) (TEA: 20 uM) in OCT2-expressing HEK293 cells,Confirmatory,12438515.0,
262,678969,3,6,,103401549,3034034,Unspecified,81872789.0,29503.0,38.0,IC50,TP_TRANSPORTER: inhibition of TEA uptake (in the absence of bicarbonate) (TEA: 20 uM) in OCT2-expressing HEK293 cells,Confirmatory,12438515.0,
263,678995,3,6,,103401549,3034034,Unspecified,81872095.0,24904.0,0.9,IC50,TP_TRANSPORTER: inhibition of TEA uptake (in the presence of bicarbonate) (TEA: 20 uM) in OCT1-expressing HEK293 cells,Confirmatory,12438515.0,
264,678996,3,6,,103401549,3034034,Unspecified,81872095.0,24904.0,1.1,IC50,TP_TRANSPORTER: inhibition of TEA uptake (in the absence of bicarbonate) (TEA: 20 uM) in OCT1-expressing HEK293 cells,Confirmatory,12438515.0,
265,679159,2,7,,103401549,3034034,Unspecified,313104182.0,6582.0,2.6,Km,TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes,Confirmatory,9260930.0,
266,679216,1,7,,103401549,3034034,Unspecified,81872095.0,24904.0,,,"TP_TRANSPORTER: inhibition of Choline uptake (Choline: 10 uM, Quinine: 200 uM) in Xenopus laevis oocytes",Other,11553644.0,
267,679315,2,7,,103401549,3034034,Unspecified,81872095.0,24904.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,8898084.0,
268,679493,2,7,,103401549,3034034,Unspecified,3914190.0,170698.0,3.81,Ki,TP_TRANSPORTER: inhibition of Digoxin uptake in Oatp2-expressing LLC-PK1 cells,Confirmatory,11883641.0,
269,680279,1,8,,103401549,3034034,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Quinine: 20 uM) in MDR1-expressing NIH-3T3 cells",Other,14985103.0,
270,680392,1,8,,103401549,3034034,Unspecified,146345508.0,6583.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (TEA: 60 uM, Quinine: 1000 uM) in Xenopus laevis oocytes",Other,10215651.0,
271,680503,1,8,,103401549,3034034,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Doxorubicin transepithelial transport (basal to apical) (Doxorubicin: 3 uM, Quinidine: 50 uM) in MDR1-expressing LLC-PK1 cells",Other,11042226.0,
272,681126,3,6,,103401549,3034034,Unspecified,238054374.0,5243.0,87.6,IC50,TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
273,681127,3,6,,103401549,3034034,Unspecified,238054374.0,5243.0,74.4,IC50,TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
274,681131,3,6,,103401549,3034034,Unspecified,238054374.0,5243.0,22.6,IC50,TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
275,681146,3,6,,103401549,3034034,Unspecified,313104181.0,6580.0,22.9,Ki,TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing HeLa cells,Confirmatory,9655880.0,
276,681157,3,6,,103401549,3034034,Unspecified,81872095.0,24904.0,0.93,Ki,TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes,Confirmatory,7990927.0,
277,681159,3,6,,103401549,3034034,Unspecified,81872095.0,24904.0,4.1,IC50,TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes,Confirmatory,11502595.0,
278,681163,2,7,,103401549,3034034,Unspecified,238054374.0,5243.0,10.0,Km,TP_TRANSPORTER: ATP hydrolysis in reconstituted proteoliposomes,Confirmatory,8621716.0,
279,681171,3,6,,103401549,3034034,Unspecified,313104182.0,6582.0,3.4,Ki,TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes,Confirmatory,9260930.0,
280,681376,3,6,,103401549,3034034,Unspecified,81872095.0,24904.0,4.3,Ki,TP_TRANSPORTER: inhibition of MPP+ uptake in OCT1-expressing HEK293 cells,Confirmatory,8878062.0,
281,681573,2,7,,103401549,3034034,Unspecified,81872095.0,24904.0,0.27,Km,TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes,Confirmatory,8955087.0,
282,681579,3,6,,103401549,3034034,Unspecified,238054374.0,5243.0,184.9,IC50,TP_TRANSPORTER: inhibition of Tetramethylrosamine efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
283,681580,3,6,,103401549,3034034,Unspecified,238054374.0,5243.0,159.3,IC50,TP_TRANSPORTER: inhibition of JC-1 efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
284,681581,3,6,,103401549,3034034,Unspecified,238054374.0,5243.0,112.4,IC50,TP_TRANSPORTER: inhibition of Fluo-3-AM efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
285,681582,3,6,,103401549,3034034,Unspecified,238054374.0,5243.0,167.8,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in NIH-3T3-G185 cells,Confirmatory,11716514.0,
286,681632,3,6,,103401549,3034034,Unspecified,81872789.0,29503.0,55.0,Ki,TP_TRANSPORTER: inhibition of TEA uptake in Xenopus laevis oocytes,Confirmatory,11502595.0,
287,681634,1,7,,103401549,3034034,Unspecified,81872789.0,29503.0,,,"TP_TRANSPORTER: inhibition of TEA uptake (apical to cell)(TEA: 100 uM, Quinine: 200 uM) in OCT2-expressing MDCK cells",Other,10600936.0,
288,681642,1,7,,103401549,3034034,Unspecified,81872789.0,29503.0,,,"TP_TRANSPORTER: inhibition of Choline uptake (Choline: 10 uM, Quinine: 200 uM) in Xenopus laevis oocytes",Other,11553644.0,
289,681643,1,7,,103401549,3034034,Unspecified,81872789.0,29503.0,,,"TP_TRANSPORTER: TEA uptake (TEA: 200 uM, Quinine: 200 uM) in Xenopus laevis oocytes",Other,10600936.0,
290,681950,1,7,,103401549,3034034,Unspecified,313104181.0,6580.0,,,"TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.85 uM, Quinine: 1000 uM) in Xenopus laevis oocytes",Other,9187257.0,
291,682003,1,7,,103401549,3034034,Unspecified,313104182.0,6582.0,,,"TP_TRANSPORTER: inhibition of Choline uptake (Choline: 10 uM, Quinine: 200 uM) in Xenopus laevis oocytes",Other,11553644.0,
292,682052,2,7,,103401549,3034034,Unspecified,1171883.0,50572.0,76.7,Ki,TP_TRANSPORTER: inhibition of E217betaG uptake in Oatp1-expressing LLC-PK1 cells,Confirmatory,11883641.0,
293,682294,1,7,,103401549,3034034,Unspecified,8928257.0,6584.0,,,"TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, Quinine: 500 uM) in OCTN2-expressing HEK293 cells",Other,10525100.0,
294,699539,1,7,,103401549,3034034,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
295,699540,1,7,,103401549,3034034,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
296,699541,1,7,,103401549,3034034,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
297,720641,1,2,,92308761,3034034,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
298,720717,1,3,,92308761,3034034,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
299,772515,1,2,,103401549,3034034,Unspecified,,,,,Antimalarial activity against gametocytic stage of Plasmodium berghei infected in blood assessed as inhibition of ookinete formation at 10 uM after 24 hrs by Giemsa staining-based microscopic analysis relative to control,Other,23927658.0,
300,781326,1,2,,103401549,3034034,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
301,1079931,1,1,,103401549,3034034,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
302,1079932,1,1,,103401549,3034034,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
303,1079933,1,1,,103401549,3034034,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
304,1079934,1,1,,103401549,3034034,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
305,1079935,1,1,,103401549,3034034,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
306,1079936,1,1,,103401549,3034034,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
307,1079937,1,1,,103401549,3034034,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
308,1079938,1,1,,103401549,3034034,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
309,1079939,1,1,,103401549,3034034,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
310,1079940,1,1,,103401549,3034034,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
311,1079941,1,1,,103401549,3034034,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
312,1079942,1,1,,103401549,3034034,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
313,1079943,1,1,,103401549,3034034,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
314,1079944,1,1,,103401549,3034034,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
315,1079945,1,1,,103401549,3034034,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
316,1079946,1,1,,103401549,3034034,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
317,1079947,1,1,,103401549,3034034,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
318,1079948,1,1,,103401549,3034034,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
319,1079949,1,1,,103401549,3034034,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
320,1115041,1,2,,103401549,3034034,Unspecified,,,,,Haemolytic activity against Homo sapiens (human) RBC at >25 ug/ml up to 24 hr,Other,,
321,1115042,1,2,,103401549,3034034,Unspecified,,,,,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum MRC 20 infected in human red blood cells measured up to 24 hr,Other,,
322,1126676,1,1,,103401549,3034034,Unspecified,,,,,Antimalarial activity against chloroquine/quinine sensitive Plasmodium falciparum assessed as parasite growth inhibition after 48 hrs,Other,24681985.0,
323,1145606,2,1,,103401549,3034034,Unspecified,,,,,"Octanol-aqueous phase partition coefficient, log P of the compound",Other,13215.0,
324,1145607,1,1,,103401549,3034034,Unspecified,,,,,"Octanol-aqueous phase distribution coefficient, log D of the compound",Other,13215.0,
325,1145608,1,1,,103401549,3034034,Unspecified,,,,,Drug absorption in anesthetized rat colon at pH 6.8,Other,13215.0,
326,1145610,1,1,,103401549,3034034,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 6.8",Other,13215.0,
327,1145612,1,1,,103401549,3034034,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 5.3",Other,13215.0,
328,1145613,1,2,,103401549,3034034,Unspecified,,,,,Drug absorption in rat small intestine,Other,13215.0,
329,1148823,1,1,,103401549,3034034,Unspecified,,,,,"Antimalarial activity against Plasmodium berghei infected in mouse assessed as change in mean survival time at 160 mg/kg, sc",Other,781245.0,
330,1148828,1,1,,103401549,3034034,Unspecified,,,,,"Antimalarial activity against Plasmodium berghei infected in mouse assessed as change in mean survival time at 640 mg/kg, sc",Other,781245.0,
331,1148830,1,1,,103401549,3034034,Unspecified,,,,,"Toxicity in mouse infected with Plasmodium berghei assessed as animal death at 640 mg/kg, sc",Other,781245.0,
332,1148831,1,1,,103401549,3034034,Inactive,,,,,Phototoxicity in ip dosed mouse,Other,781245.0,
333,1159620,1,1,,103401549,3034034,Active,,,,,Summary of drug indications.,Other,,
334,1183264,1,1,,103401549,3034034,Unspecified,,,,,Antimalarial activity against chloroquine ane quinine-sensitive ring stage of Plasmodium falciparum assessed as inhibition of parasite growth after 48 hrs,Other,25016227.0,
335,1201059,1,1,,103401549,3034034,Active,,,0.113,IC50,Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1,Confirmatory,25747499.0,
336,1201061,1,1,,103401549,3034034,Active,,,0.08,IC50,Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7,Confirmatory,25747499.0,
337,1201063,1,1,,103401549,3034034,Active,,,0.19899999999999998,IC50,Antiplasmodial activity against chloroquine/mefloquine-resistant Plasmodium falciparum SKF58,Confirmatory,25747499.0,
338,1201065,1,1,,103401549,3034034,Active,,,0.431,IC50,Antiplasmodial activity against chloroquine/mefloquine-resistant Plasmodium falciparum SRIV35,Confirmatory,25747499.0,
339,1209581,1,2,,103401549,3034034,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis,Other,21149540.0,
340,1209582,1,1,,103401549,3034034,Unspecified,,,,,Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs,Other,21149540.0,
341,1209583,1,1,,103401549,3034034,Unspecified,,,,,"Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma",Other,21149540.0,
342,1209593,1,1,,103401549,3034034,Unspecified,,,,,"Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis",Other,21149540.0,
343,1224863,1,1,,176484562,3034034,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
344,1224863,1,1,,176485073,3034034,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
345,1224905,2,1,,92308761,3034034,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
346,1224905,2,1,,92308761,3034034,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
347,1259407,1,1,,363903705,3034034,Inactive,,,,,CCRIS mutagenicity studies,Other,,
348,1259416,1,2,,375176268,3034034,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
